Beijing-based CANbridge Life Sciences, a clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has raised $25 million in Series B funding. Lapam Capital led the round with participation from Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and Wuxi App Tec.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: